June 20, 2024 03:12 PM EDT

Zealand Pharma hits early efficacy goal for amylin weight loss candidate

Nicole DeFeudis

Editor

Zealand Pharma’s amylin analogue weight loss candidate petrelintide helped patients lose a mean 8.6% of their body weight in a Phase 1b trial, meeting executives …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Zealand Pharma hits early efficacy goal for amylin weight loss candidate

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Biogen gets $250M in Royalty Pharma deal for Phase 3 lupus program

After passing on M&A offers, Abcuro raises $200M in bid to become commercial drugmaker

Exclusive: Longevity startup targets renegade proteins linked to diabetes and obesity

SpringWorks lands FDA approval for nerve tumor treatment

Biohaven lands priority review on second-chance application for neurodegenerative drug

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Zealand Phar­ma hits ear­ly ef­fi­ca­cy goal for amylin weight loss can­di­date

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Zealand Pharma hits early efficacy goal for amylin weight loss candidate